Agilent Technologies vs Edwards Lifesciences
Side-by-side comparison of AI visibility scores, market position, and capabilities
Santa Clara analytical instruments (NYSE: A) at $6.95B FY2025 revenue; Q4 +9.4% recovery from pharma destocking, LC-MS/gas chromatography leader for drug dev and food safety competing with Waters and Thermo Fisher.
About
Agilent Technologies, Inc. is a Santa Clara, California-based life sciences, diagnostics, and applied chemical analysis instruments company — publicly traded on the New York Stock Exchange (NYSE: A) as an S&P 500 Health Care component — designing, manufacturing, and supporting analytical instruments, consumables, software, and services for pharmaceutical, biopharmaceutical, food safety, environmental, clinical, and academic laboratory applications through approximately 17,000 employees worldwide. In fiscal year 2025 (ending October 2025), Agilent reported full-year revenue of $6.95 billion, with Q4 FY2025 revenue of $1.86 billion (+9.4% reported, +7.2% core growth) — accelerating from the prior year's market correction when the pharmaceutical and biopharma industry destocked lab consumables following the COVID-era inventory surge. The Life Sciences and Diagnostics Markets Group delivered Q4 FY2025 revenue of $755 million (+15% reported, +11% core), reflecting a robust recovery in pharmaceutical R&D laboratory spending. Founded in 1999 as a spinoff from Hewlett-Packard's analytical instruments division (carrying forward HP's tradition of precision measurement instruments dating to 1939), Agilent is organized around three segments: Life Sciences & Applied Markets (liquid chromatography, mass spectrometry, gas chromatography systems for drug development and food/environmental testing), Diagnostics & Genomics (pathology reagents, next-generation sequencing, FISH probes for cancer diagnostics), and Agilent CrossLab (instrument services, calibration, laboratory informatics, and consumables replacement).
Irvine CA structural heart devices (NYSE: EW) at $5.44B 2024 revenue; 60% TAVR global share, EVOQUE tricuspid +88% in Q4, Critical Care sold to BD for $4.2B, JenaValve acquisition expanding to aortic regurgitation.
About
Edwards Lifesciences Corporation is an Irvine, California-based structural heart disease and hemodynamic monitoring technology company — publicly traded on the New York Stock Exchange (NYSE: EW) as an S&P 500 Healthcare component — designing, developing, and manufacturing devices for heart valve replacement, transcatheter heart valve therapy, and cardiac critical care through approximately 15,800 employees in 100+ countries. In fiscal year 2024, Edwards reported total revenue of $5.44 billion (+8.6% year-over-year), driven by its dominant Transcatheter Aortic Valve Replacement (TAVR) franchise commanding approximately 60% global market share and 70%+ US market share. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated exceptional growth, with Q4 TMTT revenue reaching $105 million (+88% year-over-year), as the EVOQUE tricuspid replacement system gained commercial momentum. In 2024, Edwards executed a major strategic transformation: divesting its Critical Care segment (hemodynamic monitoring) to Becton Dickinson for $4.2 billion — using the proceeds to fund two acquisitions: JenaValve Technology ($1.2B combined, expanding TAVR to high-risk patients with aortic regurgitation) and Endotronix. The company concentrates its entire focus on structural heart disease therapies.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.